Merck Gets FDA Priority Review of Keytruda in Head, Neck Cancer

Datum : 11/02/2019 @ 13h32
Quelle : Dow Jones News
Name : Merck & Company (New) (MRK)
Kurs : 81.39  -1.3 (-1.57%) @ 01h59
Merck share price Chart

Merck Gets FDA Priority Review of Keytruda in Head, Neck Cancer

Merck (NYSE:MRK)
Historical Stock Chart

6 Monate : Von Jan 2019 bis Jul 2019

Click Here for more Merck Charts.
   By Colin Kellaher 

Merck & Co. (MRK) on Monday said the U.S. Food and Drug Administration accepted and granted priority review for a supplemental biologics license application for the cancer drug Keytruda in head and neck cancer.

The Kenilworth, N.J., drug maker said the sBLA seeks approval for Keytruda as monotherapy or in combination with chemotherapy for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

Merck said the sBLA filing is partly based on data from a phase 3 study in which Keytruda showed a significant improvement in overall survival compared with the standard of care.

The FDA set a target action date of June 10, Merck said.

Keytruda, a cancer drug that harnesses a patient's immune systems to fight tumors, is already marketed to treat lung, skin, bladder and other cancers.


Write to Colin Kellaher at


(END) Dow Jones Newswires

February 11, 2019 07:17 ET (12:17 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Kürzlich von Ihnen besucht
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.
P: V:de D:20190721 06:30:58